Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)

UVA Tracking #
HSR230504
Principal Investigator
Richard Hall
Contact
Contact Phone
Official Trial Title
Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
Study Description

The University of Virginia seeks adults ages 18 and over with squamous or non-squamous non-small cell lung cancer (NSCLC) that have a KRAS G12C mutation and are candidates to undergo surgery. If you are unsure if you have the KRAS G12C mutation, you may be tested for it.

The goal of this study is to assess the efficacy of treatment with a study drug called adagrasib, alone or in combination with another study drug called nivolumab, when given before cancer surgery.

You may be eligible for this study if:
- You have stage IB-IIIA NSCLC with KRAS G12C mutation
- Your NSCLC could be removed with surgery

This study involves ECG, tumor biopsy for KRAS G12C mutation testing, brain scan, CT scans, and blood draws.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Compensation

No Compensation